| Bioactivity | Alvelestat (tosylate) is an orally bioavailable, affinity and selective inhibitor of neutrophil elastase (NE) with a pIC50 value of 7.9 nM, a Ki value of 9.4 nM and a Kd value of 9.5 nM[1]. |
| Target | pIC: 7.9 nM; Ki: 9.4 nM; Kd: 9.5 nM (neutrophil elastas) |
| Invitro | Alvelestat (20 μg/mL; 16 hours; HBE and A549 cells) treatment decreases cells death and decreases the levels of IL-1β, IL-6, and TNF-α in vitro[2]. |
| Name | Alvelestat tosylate |
| CAS | 1240425-05-1 |
| Formula | C32H30F3N5O7S2 |
| Molar Mass | 717.74 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stevens T, et al. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther. 2011 Oct;339(1):313-20. [2]. Li H, et al. Neutrophil extracellular traps contribute to the pathogenesis of acid-aspiration-induced ALI/ARDS. Oncotarget. 2017 Nov 28;9(2):1772-1784. |
Alvelestat tosylate
CAS: 1240425-05-1 F: C32H30F3N5O7S2 W: 717.74
Alvelestat (tosylate) is an orally bioavailable, affinity and selective inhibitor of neutrophil elastase (NE) with a pIC
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.